J Korean Med Assoc.  2012 Sep;55(9):816-818. 10.5124/jkma.2012.55.9.816.

Policy for drug safety and its impact on the patient safety

• Park BJ

• KMID: 1787243
• DOI: http://doi.org/10.5124/jkma.2012.55.9.816

Abstract

No abstract available.

MeSH Terms

Humans
Patient Safety

Reference

1. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961. 2:1358.

2. Waxman HA. The lessons of Vioxx-drug safety and sales. N Engl J Med. 2005. 352:2576–2578.

3. World Health Organization. The importance of pharmacovigilance. 2002.

4. Wood SF, Perosino KL. Increasing transparency at the FDA: the impact of the FDA Amendments Act of 2007. Public Health Rep. 2008. 123:527–530.

5. Permanand G, Mossialos E, McKee M. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance. Clin Med. 2006. 6:87–90.

6. U.S. Food and Drug Administration. The Food and Drug Administration Amendments Act of 2007 (FDAAA). 2007.

7. European Commission. Volume 9A of the Rule Governing Medicinal Products in the European Union ; Guidelines on Pharmacovigilance for Medicinal Products for Human Use. 2008.

8. American Society of Hospital Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993. 50:305–314.